6-bromo-naphthalene-1-sulfonyl chloride | 110448-37-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 6-bromo-naphthalene-1-sulfonyl chloride
• 英文别名: 6-Brom-naphthalin-1-sulfonylchlorid；6-Bromonaphthalene-1-sulfonyl chloride
• CAS: 110448-37-8
• 化学式: C₁₀H₆BrClO₂S
• 分子量: 305.579
• InChiKey: IFROBSGHDMHEPX-UHFFFAOYSA-N

物化性质

• 沸点：
  394.8±17.0 °C(Predicted)
• 密度：
  1.732±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-bromo-naphthalene-1-sulfonyl chloride 在 吡啶 、 水 、 乙酸酐 、 sodium carbonate 、 氯乙酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 27.5h， 生成 1-[(6-bromo-1-naphthalenyl)sulfonyl]-2,4-imidazolidinedione
  参考文献：
  名称：

  Naphthalenylsulfonyl-hydantoins as aldose reductase inhibitors

  摘要：

  Accumulation of intracellular sorbitol, formed from glucose by aldose reductase, is believed to play an important role in the development of certain chronic complications of diabetes mellitus. Several 1-(naphthalenylsulfonyl)hydantoins inhibit aldose reductase isolated from bovine lens in vitro, and decrease galactitol formation in sciatic nerves of galactosemic rats in vivo. The 5-bromo analogue (entry 12, table I) was found to be the most orally active aldose reductase inhibitor of this series with an ED50 value of 8.1 mg/kg po. The 1-(naphthalenylsulfonyl)-2-thiohydantoin analogues with the exception of entry 11 (table I) which showed good in vivo activity, were either inactive or had only marginal activity.

  DOI：

  10.1016/0223-5234(91)90096-6

文献信息

• Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents
  申请人：ZENECA LIMITED

  公开号：US20030207882A1

  公开（公告）日：2003-11-06

  Compounds of formula (I), wherein G 1 is CH or N; G 2 is CH or N; R 1 is a variety of optional substituents, L 1 is (1-4C)alkylene; T 1 is CH or N; R 2 and R 3 are independently hydrogen or (1-4C)alkyl or are joined to form a ring; X 1 and X 2 represent various linking groups; Ar is phenylene or certain heteroaryl rings and Q represents a variety of aromatic or heterocyclic rings systems, and pharmaceutically acceptable salts thereof are described as useful antithrombotic and anticoagulant agents, and are selective Factor Xa inhibitors. Processes for their preparation and pharmaceutical compositions containing them are also described. 1

  式（I）的化合物，其中G1为CH或N；G2为CH或N；R1为各种可选取代基，L1为（1-4C）烷基；T1为CH或N；R2和R3独立地为氢或（1-4C）烷基或连接成环；X1和X2代表各种连接基团；Ar为苯基或特定杂环芳基，Q代表各种芳香或杂环芳基系统，及其药学上可接受的盐被描述为有用的抗血栓和抗凝血剂，并且是选择性的凝血因子Xa抑制剂。还描述了其制备方法和含有它们的药物组合物。
• Carbamate derivatives, process for producing the same and use thereof
  申请人：——

  公开号：US20040038986A1

  公开（公告）日：2004-02-26

  Novel carbamate derivatives which are useful as drugs because of inhibiting activated blood coagulation factor X and thus exerting an anticoagulant effect. Compounds represented by the formula: 1 wherein R 1 represents a group represented by the formula: 2 (wherein Y 1 represents CH═CH, etc.), which may be substituted, etc.; the ring A represents an oxo-substituted nitrogen-containing heterocyclic ring which may be further substituted; R 2 represents a hydrogen atom, optionally substituted C 1-4 alkyl, etc.; R 3 represents optionally substituted C 1-4 alkyl, etc.; and Z represents an optionally substituted nitrogen containing heterocyclic group, etc., or salts thereof.

  这是一种新型的氨基甲酸酯衍生物，由于抑制了激活的血凝血因子X而具有抗凝作用，因此可用作药物。化合物由公式1表示，其中R1表示公式2表示的基团（其中Y1表示CH═CH等），可以被取代等；环A表示氧代氮杂环环，可以进一步被取代；R2表示氢原子，可选取代的C1-4烷基等；R3表示可选取代的C1-4烷基等；Z表示可选取代的含氮杂环基团等，或其盐。
• CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1340753B1

  公开（公告）日：2006-01-11
• Sindall, Chemical news and journal of industrial science, 1889, vol. 60, p. 58
  作者：Sindall

  DOI：——

  日期：——
• XIDAKA, XIROESI;TANAKA, TOSIO;ITO, YASUO;KATO, XIDEHO;EHTTYU, EHJITI;OGAV+
  作者：XIDAKA, XIROESI、TANAKA, TOSIO、ITO, YASUO、KATO, XIDEHO、EHTTYU, EHJITI、OGAV+

  DOI：——

  日期：——